Does structural neuroimaging reveal a disturbance of iron metabolism in Parkinson's disease? Implications from MRI and TCS studies

Journal of Neural Transmission

Volumn 119, Issue 12, 2012, Pages 1523-1528

  Gröger, Adriane ^a   Berg, Daniela ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Magnetic resonance imaging; Parkinson's disease; Substantia nigra; Transcranial sonography

Indexed keywords

ARTICLE; ECHOGRAPHY; IRON METABOLISM; IRON METABOLISM DISORDER; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; SUBSTANTIA NIGRA; TRANSCRANIAL SONOGRAPHY;

HUMANS; IRON; MAGNETIC RESONANCE IMAGING; NEUROIMAGING; PARKINSON DISEASE; SUBSTANTIA NIGRA; ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL;

EID: 84876250024     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-012-0873-0     Document Type: Article

References (52)

1. Antonini A, Leenders KL, Meier D, Oertel WH, Boesiger P, Anliker M (1993) T2 relaxation time in patients with Parkinson's disease. Neurology 43:697-700
2. Atasoy HT, Nuyan O, Tunc T, Yorubulut M, Unal AE, Inan LE (2004) T2-weighted MRI in Parkinson's disease; substantia nigra pars compacta hypointensity correlates with the clinical scores. Neurol India 52:332-337
3. Bartzokis G, Cummings JL, Markham CH, Marmarelis PZ, Treciokas LJ, Tishler TA, Marder SR, Mintz J (1999) MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. Magn Reson Imaging 17:213-222
4. Baudrexel S, Nürnberger L, Rüb U, Seifried C, Klein JC, Deller T, Steinmetz H, Deichmann R, Hilker R (2010) Quantitative mapping of T1 and T2*discloses nigral and brainstem pathology in early Parkinson's disease. Neuroimage 51:512-520
5. Behnke S, Schroeder U, Dillmann U, Buchholz HG, Schreckenberger M, Fuss G, Reith W, Berg D, Krick CM (2009) Hyperechogenicity of the substantia nigra in healthy controls is related to MRI changes and to neuronal loss as determined by F-Dopa PET. Neuroimage 47:1237-1243
6. Berg D (2007) Disturbance of iron metabolism as a contributing factor to SN hyperechogenicity in Parkinson's disease: implications for idiopathic and monogenetic forms. Neurochem Res 32:1646-1654
7. Berg D (2011) Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease: yes. J Neural Transm 118:613-619
8. Berg D, Becker G, Zeiler B, Tucha O, Hofmann E, Preier M, Benz P, Jost W, Reiners K, Lange KW (1999a) Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 53:1026-1031
9. Berg D, Grote C, Rausch WD, Mäurer M, Wesemann W, Riederer P, Becker G (1999b) Iron accumulation of the substantia nigra in rats visualized by ultrasound. Ultrasound Med Biol 25:901-904
10. Berg D, Roggendorf W, Schröder U, Klein R, Tatschner T, Benz P, Tucha O, Preier M, Lange KW, Reiners K, Gerlach M, Becker G (2002) Echogenicity of the substantia nigra - association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 59:999-1005
11. Berg D, Merz B, Reiners K, Naumann M, Becker G (2005) A five year follow-up study of hyperechogenicity of the substantia nigra in Parkinson′s disease. Mov Disord 20:383-385
12. Berg D, Godau J, Walter U (2008) Transcranial sonography in movement disorders. Lancet Neurol 7:1044-1055
13. Berg D, Seppi K, Behnke S, Liepelt I, Schweitzer K, Stockner H, Wollenweber F, Gaenslen A, Mahlknecht P, Spiegel J, Godau J, Huber H, Srulijes K, Kiechl S, Bentele M, Gasperi A, Schubert T, Hiry T, Probst M, Schneider V, Klenk J, Sawires M, Willeit J, Maetzler W, Fassbender K, Gasser T, Poewe W (2011) Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons. Arch Neurol 68:932-937
14. Braffman BH, Grossman RI, Goldberg HI, Stern MB, Hurtig HI, Hackney DB, Bilaniuk LT, Zimmerman RA (1989) MR imaging of Parkinson disease with spin-echo and gradient-echo sequences. AJR Am J Roentgenol 152:159-165
15. Brass SD, Chen NK, Mulkern RV, Bakshi R (2006) Magnetic resonance imaging of iron deposition in neurological disorders. Top Magn Reson Imaging 17:31-40
16. Connor JR, Boeshore KL, Benkovic SA, Menzies SL (1994) Isoforms of ferritin have a specific cellular distribution in the brain. J Neurosci Res 37:461-465
17. De Rijk MC, Tzourio C, Breteler MMB, Dartigues JF, Amaducci L, Lopez-Pousa S, Manubens-Bertran JM, Alperovitch A, Rocca WA (1997) Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON collaborative study. J Neurol Neurosurg Psychiatry 62:10-15
18. Dexter DT, Sian J, Jenner P, Marsden CD (1993) Implications of alterations in trace element levels in brain in Parkinson's disease and other neurological disorders affecting the basal ganglia. Adv Neurol 60:273-281
19. Du G, Lewis MM, Styner M, Shaffer ML, Sen S, Yang QX, Huang X (2011) Combined R2*and diffusion tensor imaging changes in the substantia nigra in Parkinson's disease. Mov Disord 26:1627-1632
20. Gaenslen A, Unmuth B, Godau J, Liepelt I, Di Santo A, Schweitzer KJ, Gasser T, Machulla HJ, Reimold M, Marek K, Berg D (2008) The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. Lancet Neurol 7:417-424
21. Gerlach M, Ben-Shachar D, Riederer P, Youdim MB (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases. J Neurochem 63:793-807
22. Gorell JM, Ordidge RJ, Brown GG, Deniau JC, Buderer NM, Helpern JA (1995) Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 45:1138-1143
23. Graham JM, Paley MN, Grünewald RA, Hoggard N, Griffiths PD (2000) Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. Brain 123:2423-2431
24. Gupta D, Saini J, Kesavadas C, Sarma PS, Kishore A (2010) Utility of susceptibility-weighted MRI in differentiating Parkinson's disease and atypical parkinsonism. Neuroradiology 52:1087-1094
25. Haacke EM, Cheng NY, House MJ, Liu Q, Neelavalli J, Ogg RJ, Khan A, Ayaz M, Kirsch W, Obenaus A (2005) Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging 23:1-25
26. Haacke EM, Mittal S, Wu Z, Neelavalli J, Cheng YC (2009) Susceptibility-weighted imaging: technical aspects and clinical applications, part 1. AJNR Am J Neuroradiol 30:19-30
27. Huang XM, Sun B, Xue YJ, Duan Q (2010) Susceptibility-weighted imaging in detecting brain iron accumulation of Parkinson's disease. Zhonghua Yi Xue Za Zhi 90:3054-3058
28. Iranzo A, Lomeña F, Stockner H, Valldeoriola F, Vilaseca I, Salamero M, Molinuevo JL, Serradell M, Duch J, Pavía J, Gallego J, Seppi K, Högl B, Tolosa E, Poewe W, Santamaria J; Sleep Innsbruck Barcelona (SINBAR) group (2010) Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol 9:1070-1077
29. Jin L, Wang J, Zhao L, Jin H, Fei G, Zhang Y, Zeng M, Zhong C (2011) Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease. Brain 134:50-58
30. Kosta P, Argyropoulou MI, Markoula S, Konitsiotis S (2006) MRI evaluation of the basal ganglia size and iron content in patients with Parkinson's disease. J Neurol 253:26-32
31. Lotfipour AK, Wharton S, Schwarz ST, Gontu V, Schäfer A, Peters AM, Bowtell RW, Auer DP, Gowland PA, Bajaj NP (2012) High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson's disease. J Magn Reson Imaging 35:48-55
32. Martin WR, Wieler M, Gee M (2008) Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 70:1411-1417
33. Michaeli S, Oz G, Sorce DJ, Garwood M, Ugurbil K, Majestic S, Tuite P (2007) Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts. Mov Disord 22:334-340
34. Mondino F, Filippi P, Magliola U, Duca S (2002) Magnetic resonance relaxometry in Parkinson's disease. Neurol Sci 23:S87-S88
35. Nestrasil I, Michaeli S, Liimatainen T, Rydeen CE, Kotz CM, Nixon JP, Hanson T, Tuite PJ (2010) T1rho and T2rho MRI in the evaluation of Parkinson's disease. J Neurol 257:964-968
36. Ordidge RJ, Gorell JM, Deniau JC, Knight RA, Helpern JA (1994) Assessment of relative brain iron concentrations using T2-weighted and T2*-weighted MRI at 3 Tesla. Magn Reson Med 32:335-341
37. Péran P, Cherubini A, Assogna F, Piras F, Quattrocchi C, Peppe A, Celsis P, Rascol O, Démonet JF, Stefani A, Pierantozzi M, Pontieri FE, Caltagirone C, Spalletta G, Sabatini U (2010) Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain 133:3423-3433
38. Riederer P, Rausch WD, Schmidt B, Kruzik P, Konradi C, Sofic E, Danielczyk W, Fischer M, Ogris E (1988) Biochemical fundamentals of Parkinson's disease Mt. Sinai J Med 55:21-28
39. Ruprecht-Dörfler P, Berg D, Tucha O, Benz P, Meier-Meitinger M, Alders GL, Lange KW, Becker G (2003) Echogenicity of the substantia nigra in relatives of patients with sporadic Parkinson's disease. NeuroImage 18:416-422
40. Rutledge JN, Schallert T, Hall S (1993) Magnetic resonance imaging in parkinsonisms. Adv Neurol 60:529-534
41. Ryvlin P, Broussolle E, Piollet H, Viallet F, Khalfallah Y, Chazot G (1995) Magnetic resonance imaging evidence of decreased putamenal iron content in idiopathic Parkinson's disease. Arch Neurol 52:583-588
42. Savoiardo M, Girotti F, Strada L, Ciceri E (1994) Magnetic resonance imaging in progressive supranuclear palsy and other parkinsonian disorders. J Neural Transm Suppl 42:93-110
43. Schuff N (2009) Potential role of high-field MRI for studies in Parkinson's disease. Mov Disord 24:S684-S690
44. Sofic E, Riederer P, Heinsen H, Beckmann H, Reynolds GP, Hebenstreit G, Youdim MB (1988) Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 74:199-205
45. Solomon I (1955) Relaxation processes in a system of two spins. Phys Rev 99:559-565
46. Vymazal J, Brooks RA, Baumgarner C, Tran V, Katz D, Bulte JW, Bauminger R, Di Chiro G (1996) The relation between brain iron and NMR relaxation times: an in vitro study. Magn Reson Med 35:56-61
47. Vymazal J, Righini A, Brooks RA, Canesi M, Mariani C, Leonardi M, Pezzoli G (1999) T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content. Radiology 211:489-495
48. Wallis LI, Paley MN, Graham JM, Grünewald RA, Wignall EL, Joy HM, Griffiths PD (2008) MRI assessment of basal ganglia iron deposition in Parkinson's disease. J Magn Reson Imaging 28:1061-1067
49. Wang Y, Butros SR, Shuai X, Dai Y, Chen C, Liu M, Haacke EM, Hu J, Xu H (2012) Different iron-deposition patterns of multiple system atrophy with predominant parkinsonism and idiopathetic Parkinson diseases demonstrated by phase-corrected susceptibility-weighted imaging. AJNR Am J Neuroradiol 33:266-273
50. Zecca L, Berg D, Arzberger T, Ruprecht P, Rausch WD, Musico M, Tampellini T, Riederer P, Gerlach M, Becker G (2005) In vivo detection of iron and neuromelanin by transcranial sonography a new approach for early detection of substantia nigra damage. Mov Disord 20:1278-1285
51. Zhang W, Sun SG, Jiang YH, Qiao X, Sun X, Wu Y (2009) Determination of brain iron content in patients with Parkinson's disease using magnetic susceptibility imaging. Neurosci Bull 25:353-360
52. Zhang J, Zhang Y, Wang J, Cai P, Luo C, Qian Z, Dai Y, Feng H (2010) Characterizing iron deposition in Parkinson's disease using susceptibility- weighted imaging: an in vivo MR study. Brain Res 1330:124-130